Skip to main content
    V

    Vertex Pharmaceuticals Inc (VRTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $537.79
    -0.81 (-0.15%)

    Market Cap: $136.56B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Vertex Pharmaceuticals Inc (VRTX) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Vertex Pharmaceuticals (VRTX) trades at 30.0x trailing earnings and 10.5x sales. Its P/E of 30.0x is above its 5-year median of 23.7x. Its forward P/E is 26.2x. The median P/E across 5 similar companies is 33.5x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 14.5% higher over the next year. Its free cash flow yield is 2.3%.

    MultipleValue
    P/E (trailing)30.0x
    Forward P/E26.2x
    Price to sales10.5x
    Price to book6.5x
    EV/EBITDA29.8x
    Price to FCF42.6x
    EV/FCF42.4x
    PEG2.3
    FCF yield2.3%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 11.1% above 27.0x, its P/S is 3.7% below 10.9x and its P/B is 4.4% below 6.8x.

    MultipleCurrent5-year median10-year median
    P/E30.0x23.7x27.0x
    P/S10.5x9.5x10.9x
    P/B6.5x6.2x6.8x
    Medians of month-end values through Oct 2026: 51 to 60 months (5-year) and 111 to 120 months (10-year).

    Valuation History

    Over the 9 of the 10 year ends shown that have a P/E, its P/E ranged from 16.9x in 2021 to 87.7x in 2016.

    Year endPriceP/EP/SP/B
    2025$453.3624.6x9.7x6.2x
    2024$402.70N/A9.5x6.4x
    2023$406.8926.7x10.7x6.0x
    2022$288.7819.4x8.3x5.4x
    2021$219.6016.9x7.5x5.6x
    2020$236.3422.9x9.9x7.2x
    2019$218.9541.1x13.6x9.4x
    2018$165.7140.5x13.8xN/A
    2017$149.8652.4x15.1x18.8x
    2016$73.6787.7x10.6x13.6x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About VRTX

    What is VRTX's forward P/E ratio?

    Vertex Pharmaceuticals has a forward P/E ratio of 26.2x.

    Is VRTX stock overvalued?

    GNG's valuation label for VRTX is Fairly valued. Its P/E of 30.0x compares with a median of 33.5x across 5 similar companies.

    What is VRTX's price to sales ratio?

    Vertex Pharmaceuticals has a price to sales ratio of 10.5x.

    What is Vertex Pharmaceuticals's average P/E ratio over 5 years?

    Vertex Pharmaceuticals's median P/E over the last 5 years is 23.7x, from 51 month-end values through Oct 2026.

    What is VRTX's PEG ratio?

    Vertex Pharmaceuticals has a PEG ratio of 2.3.